ASLN - アスラン・ファ―マシュ―ティカルズ (ASLAN Pharmaceuticals Limited)

ASLNのニュース

   Recap: ASLAN Pharmaceuticals Q4 Earnings  2022/03/25 11:47:55 Benzinga
ASLAN Pharmaceuticals (NASDAQ: ASLN ) reported its Q4 earnings results on Friday, March 25, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings ASLAN Pharmaceuticals missed estimated earnings by 14.29%, reporting an EPS of … Full story available on Benzinga.com
   ASLAN Pharmaceuticals GAAP EPS of -$0.03  2022/03/25 11:24:30 Seeking Alpha
ASLAN Pharmaceuticals press release (ASLN): Q4 GAAP EPS of -$0.03.Cash and cash equivalents of $90.2M as of December 31, 2021Shares +1.15% PM.
   ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update  2022/03/25 11:00:00 GlobeNewswire
MENLO PARK, Calif. and SINGAPORE, March 25, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent corporate activities.
   ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting  2022/03/18 11:00:00 Benzinga
- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the "Late-breaking Research: Clinical Trials" session at the 2022 American Academy of Dermatology Annual Meeting on March 26 MENLO PARK, Calif. and SINGAPORE, March 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN ), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting key efficacy and safety data from the completed Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis (AD) has been accepted for late-breaking oral presentation at the 2022 American Academy of Dermatology Annual Meeting, to be held in-person March … Full story available on Benzinga.com
   Aslan Pharmaceuticals appoints dermatology veteran Dr Alex Kaoukhov as CMO  2022/03/15 11:32:24 Seeking Alpha
ASLAN Pharmaceuticals (ASLN) has appointed Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN’s US office, effective immediately.Alex replaces Dr Kenneth Kobayashi, who has left…
   ASLAN Pharmaceuticals (ASLN) Investor Presentation  2021/10/01 19:44:46 Seeking Alpha
   Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide  2021/09/27 16:11:05 Business Insider Markets
Midway through trading Monday, the Dow traded up 0.70% to 35,041.74 while the NASDAQ fell 0.51% to 14,970.85. The SP also rose, gaining 0.02% to 4,456.20. The U.S. has the highest number of coronavirus cases
   ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis  2021/09/27 10:00:17 ASLAN Pharmaceuticals
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p
   ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis  2021/09/27 10:00:00 Intrado Digital Media
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile
   ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference  2021/09/22 11:00:00 Intrado Digital Media
MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20am ET. The conference will be held from September 27 to September 30, 2021.
   Is it time to Buy before this weeks earning report ASLAN Pharmaceuticals (NASDAQ:ASLN)  2021/07/19 13:21:00 Stock Market Daily
Earnings results for ASLAN Pharmaceuticals , Analyst Opinion on ASLAN Pharmaceuticals , Earnings and Valuation of (NASDAQ:ASLN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Is it time to Buy before this weeks earning report ASLAN Pharmaceuticals (NASDAQ:ASLN) appeared first on .
   ASLAN Pharmaceuticals Ltd - ADR Shares Close the Week 20.2% Lower - Weekly Wrap  2021/07/17 17:33:37 Kwhen Finance
ASLAN Pharmaceuticals Ltd - ADR (ASLN) shares closed this week 20.2% lower than it did at the end of last week. The stock is currently up 48.6% year-to-date, up 47.0% over the past 12 months, and down 51.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Shares traded as high as $3.37 and as low as $2.71 this week.Shares closed 59.7% below its 52-week high and 115.9% above its 52-week low.Trading volume this week was 79.3% lower than the 10-day average and 48.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 5.9% lower than its 5-day moving average, 16.3% lower than its 20-day moving average, and 16.1% lower than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -270.7% The company's stock price performance over the past 12 months beats the peer average by -352.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development  2021/07/13 12:03:49 Benzinga
ASLAN Pharmaceuticals (NASDAQ: ASLN ) has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt Full story available on Benzinga.com
   ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures  2021/07/13 11:00:00 Intrado Digital Media
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003 Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003
   Housing Starts, Wholesale Trade Featured in Canada Next Week  2021/07/09 20:54:00 Baystreet Canada
Monday U.S. Featured Earnings Simulations Plus, Inc. (NASDAQ: SLP) (Q3) EPS projected for 17 cents, compared to 20 cents in the prior-year quarter. ASLAN Pharmaceuticals (NASDAQ:ASLN) (Q1) EPS projected for loss of 11 cents, compared to loss of 10

calendar